

In the claims:

1-32. (cancelled)

33. (amended) An antibody or fragment thereof which binds to a B7RP1 polypeptide of amino acid residues 1-322 or 47-322 as set forth in Figure 2A (SEQ ID NO:7) or a mature form thereof.

34. (amended) An antibody or fragment thereof which binds to a B7RP1 polypeptide of amino acid residues 1-288 or amino acid residues 19-288, 20-288, 21-288, 22-288, 24-288 or 28-288 as set forth in Figure 3A (SEQ ID NO:12) or a mature form thereof.

35. (amended) An antibody or fragment thereof which binds to a B7RP1 polypeptide of amino acid residues 1-302 or amino acid residues 19-302, 20-302, 21-302, 22-302, 24-302 or 28-302 as set forth in Figure 12A (SEQ ID NO:17) or a mature form thereof.

36. (amended) An antibody or fragment thereof which specifically binds to a mature form of a B7RP1 polypeptide as set forth in Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17) ~~but does not bind to the mature form of a B7RP1 polypeptide of Figure 2A (SEQ ID NO:7).~~

37. (amended) An antibody or fragment thereof which binds to a mature form of a B7RP1 polypeptide as set forth in ~~Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17)~~ and to a mature form of a B7RP1 polypeptide of as set forth in Figure 2A (SEQ ID NO:7).

38. (previously presented) The antibody or fragment of Claims 34, 35, 36 or 37 which binds to a membrane-associated form of a B7RP1 polypeptide of Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17).

39. **(previously presented)** The antibody or fragment of Claims 34, 35, 36 or 37 which binds to a soluble form of a B7RP1 polypeptide of Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17).

40. **(previously presented)** The antibody or fragment of Claims 34, 35, 36 or 37 which binds to an extracellular domain, or fragment thereof, of a B7RP1 polypeptide of Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17).

41. **(previously presented)** The antibody or fragment of Claims 34, 35, 36 or 37 which partially or completely blocks the binding of B7RP1 to CRP1.

42. **(amended)** The antibody or fragment of Claims 34, 35, 36 or 37 which is an agonist antibody that increases B7RP-1 mediated immune costimulatory activity.

43. **(amended)** The antibody or fragment of Claims 34, 35, 36 or 37 which is an antagonist antibody that decreases B7RP-1 mediated immune costimulatory activity.

44. **(amended)** The antibody or fragment of Claims 34, 35, 36 or 37 which partially or completely inhibits B7RP-1 mediated immune costimulatory activity.

45. **(previously presented)** An antibody or fragment thereof which binds to a polypeptide encoded by the nucleotide sequence as set forth in Figure 2A (SEQ ID NO: 6).

46. **(amended)** An antibody or fragment thereof which binds to a polypeptide encoded by the nucleotide sequence as set forth in ~~of~~ Figure 3A (SEQ ID NO: 11) or Figure 12A (SEQ ID NO: 16).

47. **(amended)** ~~The~~ An antibody or fragment ~~of Claim 45~~ which binds to a soluble form of B7RP1, wherein B7RP1 is encoded by the nucleic acid of Figure 3A (SEQ ID NO:11) or Figure 12A (SEQ ID NO:16).

48. **(previously presented)** The antibody of Claims 34, 35, 36 or 37 which is a monoclonal antibody.

49. **(previously presented)** The antibody of Claims 34, 35, 36 or 37 which is a chimeric antibody.

50. **(previously presented)** The antibody of Claims 34, 35, 36 or 37 which is a single chain antibody.

51. **(previously presented)** The antibody of Claims 34, 35, 36 or 37 which is a bispecific antibody.

52. **(previously presented)** The antibody of Claims 34, 35, 36 or 37 which is a CDR-grafted or humanized antibody.

53. **(previously presented)** The antibody of Claims 34, 35, 36 or 37 which is a human antibody.

54. **(previously presented)** A pharmaceutical composition comprising the antibody of Claims 34, 35, 36 or 37 and a carrier, diluent, and/or excipient.